We searched PubMed from Jan 1, 2000, to Dec 1, 2015, using the terms “otitis media and vaccines and bacteria” and “otitis media and biofilms”, and selected the most recent relevant articles. Only articles in English were reviewed. Relevant references included in these publications were also used. We added additional references from our personal files as needed.
ReviewPrevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease
Introduction
Otitis media is a common multifactorial, polymicrobial disease of the middle ear cavity of children, ranging from uncomplicated, often asymptomatic cases to protracted manifestations, including recurrent, non-responsive, and spontaneously draining infection, and chronic disease with effusion. The most frequently involved bacterial pathogens are Streptococcus pneumoniae, non-typeable Haemophilus influenzae (NTHi), and, to a lesser extent, Moraxella catarrhalis and Streptococcus pyogenes.1, 2, 3, 4 Among children, otitis media is a leading cause of clinic visits, antibiotic prescriptions, and surgical procedures.5, 6, 7 Before the introduction of pneumococcal conjugate vaccines (PCVs), peak incidence was age 6–11 months; by age 3 years, up to 85% of children will have had one or more episodes, of whom up to 20% had recurrent infections (ie, three or more episodes) by age 1 year and up to 40% will have six or more episodes during their lifetime.5 Most acute cases in children resolve spontaneously,8 and recovery depends on factors such as age and disease severity. The two main strategies for initial management are watchful waiting (ie, wait for spontaneous resolution) or immediate antibiotic treatment,9 although data for the long-term benefits of antibiotic use are limited.10
Regardless of treatment strategy, recurrent otitis media can result in permanent sequelae and complications, including hearing impairment, speech delay, and, in rare cases, intracranial and extracranial complications.11 Recurrent, non-responsive, and spontaneously draining otitis media and their sequelae, chronic otitis media with effusion (which we collectively name in this Review as complex otitis media), can be costly. In the USA, estimated national medical expenditures for otitis media and related illness reached US$2·8 billion in 2006.12 Worldwide, chronic secretory otitis media occurs in 65 million to 330 million people each year, 50% of whom develop temporary or prolonged hearing loss.13 Thus, effective preventive measures are of paramount importance.
Since PCVs target a limited number of serotypes, their efficacy against all-cause otitis media episodes is modest, and the reduction in incidence was not significant in most pre-licensure studies;14 however, in longer-term studies they have shown specific effects on the burden of complex otitis media.2, 15, 16 Although S pneumoniae is not the most common pathogen recovered in complex disease,17, 18, 19, 20 results from early clinical trials showed that prevention of pneumococcal otitis media by PCVs was linked to reduction in recurrent and chronic infection with effusion in long-term follow-ups.21, 22, 23, 24, 25 Subsequently, in several studies done after widespread implementation of vaccination programmes, substantial reductions were reported in recurrent infections, ventilation tube insertion, otitis media-related antibiotic use, and medical service use.16, 26, 27, 28, 29
We hypothesise that widespread use of PCVs led to reductions in early acute otitis media episodes caused by vaccine-type S pneumoniae, which in turn abrogated the subsequent pathogenic process that leads to complex otitis media, reducing the disease burden beyond that directly caused by vaccine-type serotypes. In this Review, we describe the complexity of sequential otitis media infections and, on the basis of clinical evidence, discuss how PCVs potentially reduce progression to complex otitis media (often caused by non-vaccine-type S pneumoniae and pathogens other than S pneumoniae) by preventing early episodes of otitis media.
Section snippets
Microbial complexity: associated bacterial pathogens
The cause of otitis media is multifactorial and often polymicrobial. Its pathogenesis and clinical presentation depend on anatomical and physiological variations in patients, environmental factors, and associated pathogens.4, 30 Pathogen-specific factors and their interaction with the host determine disease presentation, severity, and persistence. Viruses certainly have an important role in the pathogenesis and cause of this disease,4, 31 but this discussion is beyond the scope of our Review.
Clinical presentation: the disease continuum hypothesis
Although direct evidence might be incomplete, available data for a proportion of patients suggest that the complex interplay between pathogens results in a disease continuum from early acute otitis media infection enriched with S pneumoniae2, 17, 50, 51 to a subsequent polymicrobial, complex, and persistent disease (figure 1). Pathogenesis and disease presentation vary depending on the causative agents. As shown by Palmu and colleagues (figure 2),51 acute spontaneous perforations (which suggest
Prevention: vaccination against S pneumoniae can modify the otitis media continuum
Nasopharyngeal bacterial colonisation patterns are associated with otitis media risk and presentation. Early S pneumoniae colonisation is associated with increased colonisation of additional bacterial species, including NTHi, and an elevated frequency of parent-reported respiratory tract infections.108 This finding suggests that an initial infection with invasive pneumococcal strains can predispose children to more complex forms of otitis media. Importantly, the composition of microbiota
Conclusion
S pneumoniae and NTHi are responsible for most cases of otitis media worldwide, although their contribution to the disease continuum varies. S pneumoniae is more frequently responsible for early episodes of otitis media and potentially initiates middle-ear damage, leading to a disease cascade that results in subsequent polymicrobial infections, which are generally associated with NTHi and biofilms (figure 6A). The ability of these associated otopathogens to form biofilms is key to the
Search strategy and selection criteria
References (141)
- et al.
Otitis media
Lancet
(2004) - et al.
Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3–4 trial
Lancet Infect Dis
(2014) - et al.
How to compare the efficacy of conjugate vaccines to prevent acute otitis media?
Vaccine
(2009) - et al.
Microbial profiling does not differentiate between childhood recurrent acute otitis media and chronic otitis media with effusion
Int J Pediatr Otorhinolaryngol
(2013) - et al.
Brief review of the clinical effectiveness of PREVENAR against otitis media
Vaccine
(2007) - et al.
Serotype replacement in disease after pneumococcal vaccination
Lancet
(2011) - et al.
Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage
Vaccine
(2011) - et al.
Prevention of otitis media: now a reality?
Vaccine
(2009) - et al.
Predominance of nontypeable Haemophilus influenzae in children with otitis media following introduction of a 3+0 pneumococcal conjugate vaccine schedule
Vaccine
(2011) The burden of otitis media
Vaccine
(2000)
Surgery for otitis media and infectious susceptibility in 10-year old school children
Int J Pediatr Otorhinolaryngol
Otitis media with effusion in children with cleft lip and palate: a narrative review
Int J Pediatr Otorhinolaryngol
Otitis media in children with vertically-acquired HIV infection: the Great Ormond Street Hospital experience
Int J Pediatr Otorhinolaryngol
Epidemiology and pathogenesis of chronic suppurative otitis media: implications for prevention and treatment
Int J Pediatr Otorhinolaryngol
Microbiology of bacteria causing recurrent acute otitis media (AOM) and AOM treatment failure in young children in Spain: shifting pathogens in the post-pneumococcal conjugate vaccination era
Int J Pediatr Otorhinolaryngol
Acute otitis media: bacteriology and bacterial resistance in 205 pediatric patients
Int J Pediatr Otorhinolaryngol
Antibiotic resistance of bacteria in biofilms
Lancet
Identification of adenoid biofilms in chronic rhinosinusitis
Int J Pediatr Otorhinolaryngol
Acute otitis media in children: current epidemiology, microbiology, clinical manifestations, and treatment
Chang Gung Med J
Mixed pneumococcal-nontypeable Haemophilus influenzae otitis media is a distinct clinical entity with unique epidemiologic characteristics and pneumococcal serotype distribution
J Infect Dis
One third of middle ear effusions from children undergoing tympanostomy tube placement had multiple bacterial pathogens
BMC Pediatr
Otitis media: viruses, bacteria, biofilms and vaccines
Med J Aust
The diagnosis and management of acute otitis media
Pediatrics
Antibiotics for acute otitis media in children
Cochrane Database Syst Rev
Watchful waiting versus immediate antibiotic treatment in the management of acute otitis media in children
Curr Infect Dis Rep
Update on otitis media—prevention and treatment
Infect Drug Resist
Panel 8: Complications and sequelae
Otolaryngol Head Neck Surg
Medical Expenditure Panel Survey (statistical brief #228): Ear infections (otitis media) in children (0–17): use and expenditures, 2006
Burden of disease caused by otitis media: systematic review and global estimates
PLoS One
Impact of pneumococcal conjugate vaccination on otitis media: a systematic review
Clin Infect Dis
Pneumococcal conjugate vaccines and otitis media: an appraisal of the clinical trials
Int J Otolaryngol
Potential contribution by nontypable Haemophilus influenzae in protracted and recurrent acute otitis media
Pediatr Infect Dis J
Epidemiologic study of conjunctivitis–otitis syndrome
Pediatr Infect Dis J
Characteristics and outcomes of acute otitis media in children carrying Streptococcus pneumoniae or Haemophilus influenzae in their nasopharynx as a single otopathogen after introduction of the heptavalent pneumococcal conjugate vaccine
Pediatr Infect Dis J
Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
Pediatr Infect Dis J
Impact of the pneumococcal conjugate vaccine on otitis media
Pediatr Infect Dis J
Efficacy of a pneumococcal conjugate vaccine against acute otitis media
N Engl J Med
The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children
Pediatr Infect Dis J
Long-term effect of pneumococcal conjugate vaccines on tympanostomy tube placements
Pediatr Infect Dis J
National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States
Pediatrics
Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine
Pediatrics
Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997–2004
Pediatrics
The impact of pneumococcal conjugate vaccine on rates of myringotomy with ventilation tube insertion in Australia
Pediatr Infect Dis J
New paradigms in the pathogenesis of otitis media in children
Front Pediatr
Ten-year review of otitis media pathogens
Pediatr Infect Dis J
Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children: a systematic review
JAMA
Serotype-specific problems associated with pneumococcal conjugate vaccination
Future Microbiol
Evolving shifts in otitis media pathogens: relevance to a managed care organization
Am J Manag Care
Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media
Pediatrics
Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era
J Infect Dis
Cited by (103)
Otopathogens in the middle ear and nasopharynx of children with recurrent acute otitis media
2023, International Journal of Pediatric OtorhinolaryngologyAcute otitis media in the first two months of life and the impact of pneumococcal conjugate vaccines: A retrospective cohort study
2023, International Journal of Pediatric OtorhinolaryngologyImpact of PCV10 on pediatric pneumococcal disease burden in Brazil: time for new recommendations?
2023, Jornal de PediatriaStreptococcus pneumoniae as cause of acute otitis media (AOM) in Slovak children in the pneumococcal conjugate vaccine era (2008–2019)
2023, VaccineCitation Excerpt :Moreover the effect of parallel schedules on carriage reduction is unknown. The reduction of non-vaccine serotypes (Fig. 4) is at first puzzling; however, as first hypothesized by Dagan and colleagues [20], prevention of a first episode of pneumococcal AOM prevents damage to the middle ear, which may be the pre-requisite for later episodes of AOM caused by less common and less pathogenic, non-vaccine serotypes later in live. Even AOM associated with totally unrelated bacteria like Streptococcus pyogenes or Moraxella catarrhalis might be prevented by this indirect, non-immunological effect [21].